Parameter	Unit	Placebo/Treated	Day 0	Day 30	Day 60	Day 90	Day 120	Day 150
Body Weight	lb	Placebo	27.10±0.16	26.90±0.45	26.40±0.59	26.70±0.54	26.60±0.87	26.40±0.99
Body Weight	lb	Treated	24.80±1.80	26.80±1.80	24.80±2.10	25.10±2.00	25.20±2.00	25.30±2.00
Heart Rate	Beats/min	Placebo	112.00±0.00	124.00±5.70	122.00±4.70	138.00±0.90	134.00±2.80	140.00±1.90
Heart Rate	Beats/min	Treated	124.70±2.60	124.70±2.90	128.20±2.50	124.90±2.60	126.70±3.50	125.60±3.00
Body Temperature	ºF	Placebo	101.70±0.14	101.30±0.24	102.00±0.16	101.90±0.05	102.60±0.19	102.60±0.07
Body Temperature	ºF	Treated	102.10±0.35	101.80±0.25	101.70±0.25	101.70±0.15	101.70±0.16	101.70±0.22

Values are means±SEM; Normal heart rate= 70-160 beats per minute; Normal body temperature= 101-102.5 ºF.
Table 1: Effects of placebo or Crominex^® 3+ (25 mg, bid) on physical parameters in moderately arthritic dogsStatistical

Parameter	Unit	Placebo/Treated	Day 0	Day 30	Day 60	Day 90	Day 120	Day 150
BUN	mg/dl	Placebo	135.50±0.24	9.50±0.24	9.50±0.71	12.00±0.50	12.00±0.00	10.00±0.00
BUN	mg/dl	Treated	15.10±1.21	14.70±1.20	15.80±1.35	16.10±1.34	14.40±1.07	14.80±1.26
Creatinine	mg/dl	Placebo	0.94±0.09	0.87±0.03	0.91±0.05	0.92±0.10	0.97±0.04	0.83±0.07
Creatinine	mg/dl	Treated	0.89±0.09	0.90±0.10	0.91±0.10	0.84±0.08	0.90±0.11	0.83±0.08
Total bilirubin	mg/dl	Placebo	0.15±0.02	0.20±0.02	0.20±0.00	0.20±0.00	0.20±0.00	0.20±0.00
Total bilirubin	mg/dl	Treated	0.20±0.03	0.19±0.01	0.22±0.04	0.18±0.01	0.17±0.04	0.19±0.01
ALT	IU/L	Placebo	45.50±13.00	122.00±24.70	114.00±24.60	57.00±6.84	66.00±10.80	52.50±16.30
ALT	IU/L	Treated	60.90±15.10	102.20±47.80	59.20±13.30	66.00±14.80	62.00±15.30	57.70±14.30
AST	IU/L	Placebo	23.00±2.40	14.00±2.60	23.00±0.20	17.00±2.83	15.00±62.10	24.00±2.80
AST	IU/L	Treated	26.30±1.90	24.10±1.40	27.90±3.20	23.80±1.81	24.20±2.11	24.60±2.30
CK	IU/L	Placebo	208.80±44.30	68.00±11.50	153.00±16.50	85.00±1.65	105.00±1.20	196.00±52.80
CK	IU/L	Treated	160.40±24.60	124.40±29.70	231.30±99.50	108.20±16.02	130.20±45.20	150.00±31.60

Values are means±SEM; Normal reference values: BUN (7-26 mg/dl); Creatinine (0.0-1.35 mg/dl); Total bilirubin (0.1-0.6 mg/dl); ALT (10-120 IU/L); AST (15-65 IU/L); CK (60-450 IU/L).
Table 2: Effects of placebo or Crominex^® 3+ (25 mg, bid) on serum biomarkers of kidney (BUN and creatinine), liver (bilirubin, ALT, and AST), heart and skeletal muscle (CK) functions in moderately arthritic dogs

*Denotes significantly different compared to pretreated values (P< 0.05).
Figure 1: Effects of placebo or Crominex^® 3+ (25 mg, bid) on overall pain in moderately arthritic dogs. Overall pain was graded on the scale of 0 to 10 (0, no pain; 2.5, mild pain; 5, moderate pain; 7.5, severe pain; and 10, severe and constant pain). Details of pain measurement criteria are described in the text and our previous publications [19-23].

*Denotes significantly different compared to pretreated values (P< 0.05).
Figure 2: Effects of placebo or Crominex^® 3+ (25 mg, bid) on pain from limb manipulation in moderately arthritic dogs. Pain from limb manipulation was graded on a scale of 0-4 (0, no pain; 1, mild pain; 2, moderate pain; 3, severe pain; and 4, severe and constant pain). Details of pain measurement criteria are described in the text and our previous publications [19-23].

*Denotes significantly different compared to pretreated values (P< 0.05).
Figure 3: Effects of placebo or Crominex^® 3+ (25 mg, bid) on pain after physical exertion in moderately arthritic dogs. Pain after physical exertion was graded on a scale of 0-4 (0, no pain; 1, mild pain; 2, moderate pain; 3, severe pain; and 4, severe and constant pain). Details of pain measurement criteria are described in the text and our previous publications [19-23].